Cover Image

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar. This retrospective study included 328,463 Veterans 18 years of ag...

Full description

Saved in:

Bibliographic Details
Main Authors:	Samantha Walczuk (Author), Francesca E. Cunningham (Author), Xinhua Zhao (Author), Diane Dong (Author), Peter A. Glassman (Author), Donald R. Miller (Author), Deborah Khachikian (Author), Anthony Au (Author), Cedric Salone (Author), Kelly Bryan (Author), Qoua Her (Author), Sherrie L. Aspinall (Author)
Format:	Book
Published:	MDPI AG, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
by: Yiya Wang, et al.
Published: (2022)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
by: Jacques Lepercq, et al.
Published: (2012)

The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021)

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020)

The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2
by: D. Yu. Belousov, et al.
Published: (2018)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
by: Shafie AA, et al.
Published: (2020)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019)

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
by: Billings LK, et al.
Published: (2019)

Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
by: Kaleen N. Hayes, et al.
Published: (2022)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
by: Enrico Torre, et al.
Published: (2020)

Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2
by: S. К. Zyryanov, et al.
Published: (2019)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
by: Baser O, et al.
Published: (2013)

Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
by: Yazed AlRuthia, et al.
Published: (2022)

Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial
by: Shuo Zhang, et al.
Published: (2023)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
by: Torre E, et al.
Published: (2018)

Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine
by: Francesco Maria Rosanio, et al.
Published: (2021)

Descriptive study of a clinical and educational telemedicine intervention in patients with diabetes receiving glargine 300U/ml (Toujeo) in Spain: results of the T-Coach programme
by: Virginia Bellido, et al.
Published: (2023)

Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus
by: Wettergreen SA, et al.
Published: (2016)

Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation
by: Samantha Walczuk, et al.
Published: (2024)

Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self‐controlled case series analysis
by: Sherrie L. Aspinall, et al.
Published: (2020)

Concentrated insulins: the new basal insulins
by: Lamos EM, et al.
Published: (2016)

Coventional insulin versus insulin analogs
by: Anil Gomber, et al.
Published: (2019)

Insulin-derived amyloidosis: The insulin ball, amyloidoma
by: Curt Samlaska, MD, et al.
Published: (2020)

Insulin receptor trafficking steers insulin action
by: Simone Hausmann, et al.
Published: (2016)

The Expense of Insulin in Individuals with Insulin-Dependent Diabetes in Fars Province based on Prescribed Prescriptions including Insulin
by: Sanaz Amiri, et al.
Published: (2020)

Icodec insulin - revolution in diabetes type 2 insulin therapy
by: Michał Dobrzyński, et al.
Published: (2022)

Differential Effects of Polyphenols on Insulin Proteolysis by the Insulin-Degrading Enzyme
by: Qiuchen Zheng, et al.
Published: (2021)

Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets
by: Paula I. Moreira, et al.
Published: (2009)

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
by: I. N. Dyakov, et al.
Published: (2021)

Insulin Resistance
Published: (2012)

Insulin Overdose
by: Richard Stair
Published: (2008)

History of insulin
by: Celeste C. Quianzon, et al.
Published: (2012)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013)

Reappraisal of the optimal fasting time for insulin tolerance tests in mice
by: Deborah Carper, et al.
Published: (2020)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022)

The insulin-degrading enzyme as a link between insulin and neuropeptides metabolism
by: Dorota Wacławczyk, et al.
Published: (2021)